Understanding the interplay of
tumor, patient and therapy

to achieve improved
therapeutic outcomes

Exploring the interplay of
tumor, patient and therapy

For cancer patients,
time is of the essence…

According to a recent peer-reviewed study focusing on five common cancers (bladder, breast, colon, rectum, and lung), patients whose cancer treatment is delayed by even one month have, in many cases, a 6-13% higher risk of metastasis, which will ultimately result in death. This risk increases with each passing month. It’s clear that every day counts.

Immunotherapy is a
revolution, but only for
the minority who
respond

Over the last decade, ICIs targeting the PD-1/PD-L1 axis have emerged as standard-of-care treatments for NSCLC. Although ICI therapy achieves impressive long-term survival in some, the overall response rate is modest, ranging from 20-50 percent in NSCLC patients. A significant proportion of patients display innate resistance to ICIs, and many of those who derive initial clinical benefit experience disease progression at a later stage. The mechanisms underlying innate and acquired resistance to ICIs are not yet fully understood.

Many combination
protocols are studied,
but biomarker discovery
lags behind

As of early 2021, there were 2,250 active lung cancer clinical trials registered at ClinicalTrials.gov. The potential insights and findings from these clinical trials could be lifesaving, paving a clearer path to improved NSCLC treatments. Alternatively, they may result in a handful of new drugs that demonstrate efficacy in all-comers populations, in some cases with very low response rates.

Better biomarkers are
desperately needed,

but not all biomarkers
are created equal

While most precision therapies have focused on the contribution of intrinsic changes, such as genetic mutations and epigenetic alterations, within tumor cells, that predict drug resistance, a growing body of evidence demonstrates that cancer and its potential therapy can induce a range of systemic biological processes and molecular changes that enter an interplay between the tumor, the patient, and the therapy.
This interaction can potentially promote tumor regrowth and metastasis through angiogenesis, immune modulation and other resistance associated mechanisms, thereby partially or completely negating the intended therapeutic activity.


While most precision oncology tools have focused on the contribution of intrinsic factors in order to identify potential treatments (i.e. genetic mutations and epigenetic alterations), OncoHost is taking a different approach to precision medicine.
At OncoHost, we analyze the interplay between the tumor, the patient, and the therapy on the proteomic level, which allows for a comprehensive and holistic view.

Plasma proteomics
a new angle on resistance

Identifying and characterizing proteomic patterns in a patient’s plasma, which are altered by the cancer and in response to therapies, provides a more informative overview of the cancer and the host status, that can help predict a patient’s response to treatment, as well as identify appropriate next-line treatment strategies.
With one pre-treatment blood test, we can answer 3 important clinical questions:
01.
Will my patient respond to the
planned standard of care treatment?
02.
Why might my patient be resistant
to the recommended treatment
and not respond as desired?
03.
What can I do to mitigate this patient’s
resistance to treatment, and potentially
improve their outcome?

How it works

Pre-treatment
High throughput
proteomic assay
Bioinformatics and
machine learning
Protein level resistance map, a truly personalized, actionable, comprehensive disease map

Our Proteomics lab

Our lab uses high-throughput protein analysis technology to quantify the levels of thousands of proteins in a single plasma sample. The proteins include cytokines, chemokines, growth factors and enzymes associated with therapy resistance and tumor spread.

Contact us

USA office

1110 SE Cary Parkway, Suite 205
Cary, North Carolina 27518
T. (855) 950-2112
E. support@oncohost-us.com

Israel office

P.O.Box 446, 3 Hamelacha, Binyamina, Israel
T. +972 485 37558
E. info@oncohost.com